Tests a modified tumor cell vaccine in adults with advanced cancers
Tests modified, treated tumor cells as a vaccine in adults with metastatic cancer.
Plain-language title generated from the registry record
Registry title: Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Key facts
- Where
- Jerusalem, IsraelSee the site
- Phase
- Phase 1/2
Where in Israel
- Hadassah Medical OrganizationJerusalem, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hadassah Medical Organization
- Trial code
- NCT00722228
- Record updated
- 2 October 2025
- Original description
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.Read full original descriptionShow less
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.
Inclusion: One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney; Above 18 years of age; Failure of at least one chemotherapy protocol; Clinical performance status of ECOG 0,1; Absolute neutrophil count greater than 1000/mm3; Serum ALT/AST less than three times the upper limit of normal; Serum creatinine less than or equal to 1.6 mg/dl; Must be able to understand and sign the Informed Consent document.
Exclusion: Below 18 years of age; Women who are pregnant; Life expectancy of less than three months.